|
1
|
European Association for the Study of the
Liver. Electronic address: easloffice@easloffice.eu, European
Association for the Study of the Liver: EASL Clinical Practice
Guidelines: Management of hepatocellular carcinoma. J Hepatol.
69:182–236. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Davis MI, Hunt JP, Herrgard S, Ciceri P,
Wodicka LM, Pallares G, Hocker M, Treiber DK and Zarrinkar PP:
Comprehensive analysis of kinase inhibitor selectivity. Nat
Biotechnol. 29:1046–1051. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Llovet JM, Ricci S, Mazzaferro V, Hilgard
P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A,
et al: SHARP Investigators Study Group: Sorafenib in advanced
hepatocellular carcinoma. N Engl J Med. 359:378–390. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S,
Kim JS, Luo R, Feng J, Ye S, Yang TS, et al: Efficacy and safety of
sorafenib in patients in the Asia-Pacific region with advanced
hepatocellular carcinoma: A phase III randomised, double-blind,
placebo-controlled trial. Lancet Oncol. 10:25–34. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kudo M, Finn RS, Qin S, Han KH, Ikeda K,
Piscaglia F, Baron A, Park JW, Han G, Jassem J, et al: Lenvatinib
versus sorafenib in first-line treatment of patients with
unresectable hepatocellular carcinoma: A randomised phase 3
non-inferiority trial. Lancet. 391:1163–1173. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sauzay C, Petit A, Bourgeois AM, Barbare
JC, Chauffert B, Galmiche A and Houessinon A: Alpha-foetoprotein
(AFP): A multi-purpose marker in hepatocellular carcinoma. Clin
Chim Acta. 463:39–44. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bruix J, Reig M and Sherman M:
Evidence-based diagnosis, staging, and treatment of patients with
hepatocellular carcinoma. Gastroenterology. 150:835–853. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Personeni N, Bozzarelli S, Pressiani T,
Rimassa L, Tronconi MC, Sclafani F, Carnaghi C, Pedicini V,
Giordano L and Santoro A: Usefulness of alpha-fetoprotein response
in patients treated with sorafenib for advanced hepatocellular
carcinoma. J Hepatol. 57:101–107. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sauzay C, Louandre C, Bodeau S, Anglade F,
Godin C, Saidak Z, Fontaine JX, Usureau C, Martin N, Molinie R, et
al: Protein biosynthesis, a target of sorafenib, interferes with
the unfolded protein response (UPR) and ferroptosis in
hepatocellular carcinoma cells. Oncotarget. 9:8400–8414. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Manié SN, Lebeau J and Chevet E: Cellular
mechanisms of endoplasmic reticulum stress signaling in health and
disease. 3. Orchestrating the unfolded protein response in
oncogenesis: An update. Am J Physiol Cell Physiol. 307:C901–C907.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Raskopf E, Vogt A, Sauerbruch T and
Schmitz V: siRNA targeting VEGF inhibits hepatocellular carcinoma
growth and tumor angiogenesis in vivo. J Hepatol. 49:977–984. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Goel HL and Mercurio AM: VEGF targets the
tumour cell. Nat Rev Cancer. 13:871–882. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Castillo J, Erroba E, Perugorría MJ,
Santamaría M, Lee DC, Prieto J, Avila MA and Berasain C:
Amphiregulin contributes to the transformed phenotype of human
hepatocellular carcinoma cells. Cancer Res. 66:6129–6138. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xu Q, Chiao P and Sun Y: Amphiregulin in
Cancer: New Insights for Translational Medicine. Trends Cancer.
2:111–113. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ezzoukhry Z, Louandre C, Trécherel E,
Godin C, Chauffert B, Dupont S, Diouf M, Barbare JC, Mazière JC and
Galmiche A: EGFR activation is a potential determinant of primary
resistance of hepatocellular carcinoma cells to sorafenib. Int J
Cancer. 131:2961–2969. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Blivet-Van Eggelpoël MJ, Chettouh H,
Fartoux L, Aoudjehane L, Barbu V, Rey C, Priam S, Housset C,
Rosmorduc O and Desbois-Mouthon C: Epidermal growth factor receptor
and HER-3 restrict cell response to sorafenib in hepatocellular
carcinoma cells. J Hepatol. 57:108–115. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lencioni R: New data supporting modified
RECIST (mRECIST) for Hepatocellular Carcinoma. Clin Cancer Res.
19:1312–1314. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Abou-Alfa GK, Schwartz L, Ricci S, Amadori
D, Santoro A, Figer A, De Greve J, Douillard JY, Lathia C, Schwartz
B, et al: Phase II study of sorafenib in patients with advanced
hepatocellular carcinoma. J Clin Oncol. 24:4293–4300. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Louandre C, Ezzoukhry Z, Godin C, Barbare
JC, Mazière JC, Chauffert B and Galmiche A: Iron-dependent cell
death of hepatocellular carcinoma cells exposed to sorafenib. Int J
Cancer. 133:1732–1742. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Houessinon A, François C, Sauzay C,
Louandre C, Mongelard G, Godin C, Bodeau S, Takahashi S, Saidak Z,
Gutierrez L, et al: Metallothionein-1 as a biomarker of altered
redox metabolism in hepatocellular carcinoma cells exposed to
sorafenib. Mol Cancer. 15:382016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tsuchiya K, Asahina Y, Matsuda S, Muraoka
M, Nakata T, Suzuki Y, Tamaki N, Yasui Y, Suzuki S, Hosokawa T, et
al: Changes in plasma vascular endothelial growth factor at 8 weeks
after sorafenib administration as predictors of survival for
advanced hepato-cellular carcinoma. Cancer. 120:229–237. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Han SX, Bai E, Jin GH, He CC, Guo XJ, Wang
LJ, Li M, Ying X and Zhu Q: Expression and clinical significance of
YAP TAZ, and AREG in hepatocellular carcinoma. J Immunol Res 2014.
2613652014.
|
|
24
|
Zhu AX, Kang YK, Rosmorduc O, Evans TR,
Santoro A, Ross P, Gane E, Vogel A, Jeffers M, Meinhardt G, et al:
Biomarker analyses of clinical outcomes in patients with advanced
hepatocellular carcinoma treated with sorafenib with or without
erlotinib in the SEARCH trial. Clin Cancer Res. 22:4870–4879. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Booth L, Shuch B, Albers T, Roberts JL,
Tavallai M, Proniuk S, Zukiwski A, Wang D, Chen CS, Bottaro D, et
al: Multi-kinase inhibitors can associate with heat shock proteins
through their NH2-termini by which they suppress chaperone
function. Oncotarget. 7:12975–12996. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shi YH, Ding ZB, Zhou J, Hui B, Shi GM, Ke
AW, Wang XY, Dai Z, Peng YF, Gu CY, et al: Targeting autophagy
enhances sorafenib lethality for hepatocellular carcinoma via ER
stress-related apoptosis. Autophagy. 7:1159–1172. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shimizu S, Takehara T, Hikita H, Kodama T,
Tsunematsu H, Miyagi T, Hosui A, Ishida H, Tatsumi T, Kanto T, et
al: Inhibition of autophagy potentiates the antitumor effect of the
multikinase inhibitor sorafenib in hepatocellular carcinoma. Int J
Cancer. 131:548–557. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hetz C, Chevet E and Oakes SA: Erratum:
Proteostasis control by the unfolded protein response. Nat Cell
Biol. 17:829–838. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Galmiche A, Sauzay C, Houessinon A,
Chauffert B and Pluquet O: Probing Tumour Proteostasis and the UPR
with Serum Markers. Trends Cancer. 2:219–221. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Houessinon A, Gicquel A, Bochereau F,
Louandre C, Nyga R, Godin C, Degonville J, Fournier E, Saidak Z,
Drullion C, et al: Alpha-fetoprotein is a biomarker of unfolded
protein response and altered proteostasis in hepatocellular
carcinoma cells exposed to sorafenib. Cancer Lett. 370:242–249.
2016. View Article : Google Scholar : PubMed/NCBI
|
